Carlisle J B, Stevenson C A
NHS, Department of Anaesthetics, Torbay Hospital, Lawes Bridge, Torquay, Devon, UK EX6 7LU.
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD004125. doi: 10.1002/14651858.CD004125.pub2.
Drugs can prevent postoperative nausea and vomiting, but their relative efficacies and side effects have not been compared within one systematic review.
The objective of this review was to assess the prevention of postoperative nausea and vomiting by drugs and the development of any side effects.
We searched The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 2, 2004), MEDLINE (January 1966 to May 2004), EMBASE (January 1985 to May 2004), CINAHL (1982 to May 2004), AMED (1985 to May 2004), SIGLE (to May 2004), ISI WOS (to May 2004), LILAC (to May 2004) and INGENTA bibliographies.
We included randomized controlled trials that compared a drug with placebo or another drug, or compared doses or timing of administration, that reported postoperative nausea or vomiting as an outcome.
Two authors independently assessed trial quality and extracted outcome data.
We included 737 studies involving 103,237 people. Compared to placebo, eight drugs prevented postoperative nausea and vomiting: droperidol, metoclopramide, ondansetron, tropisetron, dolasetron, dexamethasone, cyclizine and granisetron. Publication bias makes evidence for differences among these drugs unreliable. The relative risks (RR) versus placebo varied between 0.60 and 0.80, depending upon the drug and outcome. Evidence for side effects was sparse: droperidol was sedative (RR 1.32) and headache was more common after ondansetron (RR 1.16).
AUTHORS' CONCLUSIONS: Either nausea or vomiting is reported to affect, at most, 80 out of 100 people after surgery. If all 100 of these people are given one of the listed drugs, about 28 would benefit and 72 would not. Nausea and vomiting are usually less common and, therefore, drugs are less useful. For 100 people, of whom 30 would vomit or feel sick after surgery if given placebo, 10 people would benefit from a drug and 90 would not. Between one to five patients out of every 100 people may experience a mild side effect, such as sedation or headache, when given an antiemetic drug. Collaborative research should focus on determining whether antiemetic drugs cause more severe, probably rare, side effects. Further comparison of the antiemetic effect of one drug versus another is not a research priority.
药物可预防术后恶心和呕吐,但在一项系统评价中尚未对它们的相对疗效和副作用进行比较。
本评价的目的是评估药物对术后恶心和呕吐的预防作用以及任何副作用的发生情况。
我们检索了Cochrane对照试验中心注册库(CENTRAL)(Cochrane图书馆,2004年第2期)、MEDLINE(1966年1月至2004年5月)、EMBASE(1985年1月至2004年5月)、CINAHL(1982年至2004年5月)、AMED(1985年至2004年5月)、SIGLE(至2004年5月)、ISI科学网(至2004年5月)、LILAC(至2004年5月)和Ingenta书目。
我们纳入了比较一种药物与安慰剂或另一种药物,或比较给药剂量或时间,并将术后恶心或呕吐作为结局报告的随机对照试验。
两位作者独立评估试验质量并提取结局数据。
我们纳入了737项研究,涉及103237人。与安慰剂相比,有八种药物可预防术后恶心和呕吐:氟哌利多、甲氧氯普胺、昂丹司琼、托烷司琼、多拉司琼、地塞米松、赛克利嗪和格拉司琼。发表偏倚使得这些药物之间差异的证据不可靠。与安慰剂相比的相对危险度(RR)在0.60至0.80之间,具体取决于药物和结局。副作用的证据较少:氟哌利多有镇静作用(RR 1.32),昂丹司琼后头痛更常见(RR 1.16)。
据报道,术后最多100人中,有恶心或呕吐症状的人最多80人。如果这100人都服用所列药物之一,约28人会受益,72人不会受益。恶心和呕吐通常不太常见,因此药物的用处较小。对于100人,如果给予安慰剂,其中30人术后会呕吐或感到恶心,那么服用药物的话,10人会受益,90人不会受益。每100人中有1至5人服用止吐药时可能会出现轻度副作用,如镇静或头痛。合作研究应集中于确定止吐药是否会引起更严重、可能罕见的副作用。一种药物与另一种药物止吐效果的进一步比较不是研究重点。